Aethlon Medical heads into the week of May 9 with a short base that has been cut in half over the past month — yet the stock is barely moving, leaving the company's next earnings event and clinical trial progress as the real watchpoints.
The short interest story is the most dramatic shift in the data. Bears have dramatically reduced exposure: SI fell nearly 48% over the past month to 3.6% of the free float, a sharp retreat from the ~7% level seen through early April when short shares briefly touched 53,000. That move appeared linked to the mid-April period — around April 10, shorts halved almost overnight, from 53,000 shares to just 15,000, before partly rebuilding to the current ~27,700. The lending market is extremely loose. Availability runs at roughly 5,978% of current short interest, meaning the pool of borrowable shares dwarfs the short position by nearly 60 times — there is no sign of borrow pressure, and cost to borrow has fallen steadily from above 8% in March to just 3.8%. This is a stock where the lending market imposes essentially no constraint on future shorting or covering.
The short score of 32, while down slightly on the week, sits in the 62nd percentile for utilization rank — unremarkable but consistent with a stock that has shed short interest without attracting fresh enthusiasm. Days-to-cover ranks in the 86th percentile, which reflects more how thinly traded the stock is than any extraordinary short overhang. Options data is too stale (last reliable reading from October 2023) to draw any meaningful conclusions about current sentiment.
The only analyst on record is HC Wainwright, which initiated with a Neutral rating and a $1.50 price target in July 2025. Against a current price of $2.25, that target sits well below where the stock is trading. The Benzinga bull case points to constructive feedback from clinical sites on the Hemopurifier program — potentially accelerating enrollment and readout timelines — and positions $4.8 million in cash as adequate runway into the second half of last year. The bear case is more pointed: net losses of $1.8 million per quarter, unproven commercialisation, IP risks, and the ever-present difficulty of raising capital at a $3.5 million market cap. With EV negative, there are no conventional valuation multiples worth anchoring to here.
Institutional ownership is thin and concentrated. Armistice Capital held 84,496 shares as of end-December, representing roughly 5.4% of shares outstanding and an entry that came alongside a purchase of 70,847 shares. No other institutional holder exceeds 1.5%. Insider activity, meanwhile, is minimal in both scale and signal: three directors — Gikakis, Broenniman, and Shah — filed routine quarterly sells in March totalling less than $1,000 in aggregate value, all flagged at the lowest significance level. These are compensation-related disposals, not meaningful directional signals.
The stock slipped 2.2% on the week to $2.25, in line with the past month's modest 7.7% gain. Its closest Nasdaq peers — HSDT and PFSA — moved in opposite directions, up 4.7% and down 8.1% respectively on the week, underscoring how stock-specific dynamics dominate at this end of the market cap spectrum.
What to watch next is straightforward: the next earnings event is scheduled for June 26, and given that the stock fell 3.8% and 6.2% respectively on the day of each of its last two prints, the setup around that date is worth monitoring alongside any clinical trial enrollment update on the Hemopurifier.
See the live data behind this article on ORTEX.
Open AEMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
